San Diego, United States
Libra Therapeutics, founded in 2019 and headquartered in the United States, is a biotechnology company committed to restoring cellular balance in neurodegenerative diseases. Its unique vision, encapsulated in the slogan "Restoring Cellular Balance: Developing novel therapeutics for neurodegenerative disease," reflects its focus on developing small molecule drugs targeting conditions like ALS, FTD, Alzheimer's, Parkinson's, and Huntington's disease.
Libra Therapeutics' innovative platform aims to alter disease progression by increasing autophagy to enhance the clearance of neurotoxic proteins while also reducing their production. This dual approach offers potential breakthroughs in managing cellular disequilibrium associated with these disorders.
In its growth journey, Libra Therapeutics secured a $29.00M Series A investment on 23 September 2020, with backing from reputable investors such as Santé Ventures, Dolby Ventures, 60 Degree Capital, Epidarex Capital, Yonjin Venture, and Boehringer Ingelheim Venture Fund. This positions the company well for advancing its therapeutic developments.
